Related references
Note: Only part of the references are listed.A Direct Interaction between Leucine-rich Repeat Kinase 2 and Specific β-Tubulin Isoforms Regulates Tubulin Acetylation
Bernard M. H. Law et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors
Anthony A. Estrada et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Surfactant Secretion in LRRK2 Knock-Out Rats: Changes in Lamellar Body Morphology and Rate of Exocytosis
Pika Miklavc et al.
PLOS ONE (2014)
Di-22:6-bis(monoacylglycerol)phosphate: A clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment
Nanjun Liu et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2014)
Drug induced phospholipidosis: An acquired lysosomal storage disorder
James A. Shayman et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2013)
In situ validation of an intestinal stem cell signature in colorectal cancer
Jennifer L. Ziskin et al.
GUT (2013)
Interplay of LRRK2 with chaperone-mediated autophagy
Samantha J. Orenstein et al.
NATURE NEUROSCIENCE (2013)
Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
Daniel Ness et al.
PLOS ONE (2013)
Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs
Marco A. S. Baptista et al.
PLOS ONE (2013)
Measurement of LRRK2 and Ser910/935 Phosphorylated LRRK2 in Peripheral Blood Mononuclear Cells from Idiopathic Parkinson's Disease Patients
Nicolas Dzamko et al.
JOURNAL OF PARKINSONS DISEASE (2013)
Discovery of Highly Potent, Selective, and Brain-Penetrable Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors
Anthony A. Estrada et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Ser1292 Autophosphorylation Is an Indicator of LRRK2 Kinase Activity and Contributes to the Cellular Effects of PD Mutations
Zejuan Sheng et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Phospholipidosis in Rats Treated with Amiodarone: Serum Biochemistry and Whole Genome Micro-Array Analysis Supporting the Lipid Traffic Jam Hypothesis and the Subsequent Rise of the Biomarker BMP
Natalie Mesens et al.
TOXICOLOGIC PATHOLOGY (2012)
Comparison of urinary and serum levels of di-22:6-bis(monoacylglycerol)phosphate as noninvasive biomarkers of phospholipidosis in rats
Karol L. Thompson et al.
TOXICOLOGY LETTERS (2012)
Recent Advances in the Genetics of Parkinson's Disease
Ian Martin et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 12 (2011)
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice
Martin C. Herzig et al.
HUMAN MOLECULAR GENETICS (2011)
Biological Function of the Cellular Lipid BMP-BMP as a Key Activator for Cholesterol Sorting and Membrane Digestion
Hichem D. Gallala et al.
NEUROCHEMICAL RESEARCH (2011)
Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?
Martin Schwaiblmair et al.
CLINICAL RESEARCH IN CARDIOLOGY (2010)
Amiodarone Review of Pulmonary Effects and Toxicity
Spyros A. Papiris et al.
DRUG SAFETY (2010)
Bis(monoacylglycerol)phosphate as a non-invasive biomarker to monitor the onset and time-course of phospholipidosis with drug-induced toxicities
Elizabeth A. Tengstrand et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Mark R. Cookson
NATURE REVIEWS NEUROSCIENCE (2010)
Lysosomal Storage Disease: Revealing Lysosomal Function and Physiology
Emma J. Parkinson-Lawrence et al.
PHYSIOLOGY (2010)
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice
Youren Tong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Effect of lysosomal storage on bis(monoacylglycero)phosphate
Peter J. Meikle et al.
BIOCHEMICAL JOURNAL (2008)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
Daniel G. Healy et al.
LANCET NEUROLOGY (2008)
Update on the functional biology of Lrrk2
Heather Melrose
FUTURE NEUROLOGY (2008)
Dynamic and redundant regulation of LRRK2 and LRRK1 expression
Saskia Biskup et al.
BMC NEUROSCIENCE (2007)
LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-Linking familial and sporadic Parkinson's disease
Vincenzo Bonifati
NEUROCHEMICAL RESEARCH (2007)
Zfp423 is required for normal cerebellar development
Soren Warming et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Elisa Greggio et al.
NEUROBIOLOGY OF DISEASE (2006)
LRRK2 expression linked to dopamine-innervated areas
D Galter et al.
ANNALS OF NEUROLOGY (2006)
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity
CJ Gloeckner et al.
HUMAN MOLECULAR GENETICS (2006)
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
AB West et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism:: Evidence of a common founder across European populations
J Kachergus et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2005)
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
C Paisán-Ruíz et al.
NEURON (2004)
Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology
A Zimprich et al.
NEURON (2004)
SP-D as a marker of amiodarone-induced pulmonary toxicity
K Umetani et al.
INTERNAL MEDICINE (2002)